A real-world study on metastatic castration-sensitive prostate cancer (mCSPC) indicates that apalutamide may improve 24-month survival rates over abiraterone acetate. (NOTE: we are talking about monotherapy).
Analyzing data from the Flatiron Metastatic Prostate Cancer Core Registry, primarily involving community oncology practices, this study offers practical insights relevant to everyday clinical decisions. Dr. Neal Shore, MD, FACS, underscores the importance of these findings in supporting shared decision-making, where clinicians and patients can weigh survival benefits alongside drug tolerability and monitoring needs. While promising, the study calls for further controlled trials to validate apalutamide’s potential advantage, highlighting a need for continued research in mCSPC treatment.
Welcoming New Era of Expanded Use of Radiotherapies
The Existence of the Oligometastatic State in Prostate Cancer (and other cancers)